LABORATORIO FARMAC.ERFO (RK7) — Cash Flow Reinvestment Rate

Latest as of December 2023: 1.38x

LABORATORIO FARMAC.ERFO (RK7) has a Cash Flow Reinvestment Rate of 1.38x as of December 2023, reinvesting €1.79 Million (capex €1.45 Million plus investments €345.57K) from operating cash flow of €1.30 Million. Check cash flow quality index of LABORATORIO FARMAC.ERFO to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

1.38x
(Capex + Investments) / Operating CF

Total Reinvested

€1.79 Million
Capex + Investments

Operating Cash Flow

€1.30 Million
EUR

Capital Expenditures

€1.45 Million
EUR

LABORATORIO FARMAC.ERFO Cash Flow Reinvestment Rate (2021–2023)

Historical reinvestment intensity for LABORATORIO FARMAC.ERFO across 3 annual periods. Explore RK7 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for LABORATORIO FARMAC.ERFO (2021–2023)

Year-by-year capital reinvestment analysis for LABORATORIO FARMAC.ERFO. For live market cap and broader valuation context, see LABORATORIO FARMAC.ERFO market capitalisation.

Year Reinvestment Rate Total Reinvested (EUR) Operating CF Capex YoY Change
2023 1.38x €1.79 Million €1.30 Million €1.45 Million ▼ -44.4%
2022 2.49x €1.89 Million €761.80K €1.18 Million ▲ +806.2%
2021 0.27x €623.55K €2.27 Million €242.84K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow